Clinical Impact of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer

The discussion builds on the burden of chemotherapy-induced myelosuppression (CIM) by examining how hematologic toxicities affect the daily lives and long-term care of patients with extensive-stage small cell lung cancer (ES-SCLC). Taylor Praska, PharmD, explains that anemia, neutropenia, and thrombocytopenia extend beyond laboratory abnormalities, often resulting in debilitating fatigue, shortness of breath, dizziness, and reduced ability to perform everyday activities or participate in important life events. These complications may contribute to chemotherapy dose delays, reductions, or interruptions, which can negatively affect treatment adherence and patients' willingness to continue therapy. The panel also discusses how preserving bone marrow function during first-line treatment may help maintain eligibility for future treatment options and support continuity of care as patients progress through subsequent lines of therapy. Megan May, PharmD, reinforces the importance of addressing myelosuppression early to minimize its cumulative impact on treatment delivery, patient experience, and long-term management of ES-SCLC.